Revenue: As of FY2025 Q4, the actual value is USD 1.11 B, beating the estimate of USD 1.092 B.EPS: As of FY2025 Q4, the actual value is USD -10.22.EBIT: As of FY2025 Q4, the actual value is USD -1.244 B.培瑞克 (Perrigo Company plc) released earnings for the fourth quarter ended December 31, 2025, on February 26, 2026.<h4>Non-GAAP Measures and Adjustments</h4>The company utilizes non-GAAP financial measures to assist in evaluating performance, comparing periods, and assessing future prospects. These non-GAAP measures exclude items such as amortization expense, unusual litigation, impairment charges, restructuring charges, and acquisition and integration-related charges. Adjustments for the three and twelve months ended December 31, 2025, and December 31, 2024, included amortization expense, unusual litigation, restructuring charges and other termination benefits, impairment charges, infant formula remediation (for 2024 periods), and (gain) loss on divestitures and brand sales. Other adjustments covered infant formula, divestitures, non-GAAP tax adjustments, and foreign currency translation movement; the three months ended December 31, 2024, also included a loss on early debt extinguishment.<h4>Non-GAAP Profit Measurements</h4>Non-GAAP profit measurements may encompass adjusted gross profit, adjusted net income, adjusted operating income, adjusted diluted earnings per share, adjusted gross margin, constant currency net sales, and adjusted operating margin. The company also presents ‘CORE’ Perrigo non-GAAP measures, reflecting its go-forward business by excluding infant formula under strategic review and previously announced divestitures. CORE measures can include CORE net income, CORE net sales, CORE organic net sales, CORE gross profit, CORE operating income, CORE diluted earnings per share, CORE gross margin, and CORE operating margin, including on an organic, constant-currency basis.<h4>Outlook / Guidance</h4>培瑞克 (Perrigo Company plc) cannot reconcile its ‘All-in’ or ‘CORE’ expected organic net sales growth, adjusted gross margin, adjusted operating margin, adjusted earnings per share, adjusted diluted earnings per share, adjusted effective tax rate, net leverage, or adjusted EBITDA to the most directly comparable GAAP measures for its “Fiscal Year 2026 Outlook from Continuing Operations” without unreasonable effort. This difficulty arises from the uncertainty of non-recurring infant formula related charges, the timing and amount of restructuring charges, and the income tax effects of these items or other income tax-related events. No specific financial outlook figures were provided in this document.Note: The provided reference describes the types of non-GAAP financial measures and adjustments used by 培瑞克 (Perrigo Company plc) but does not contain specific numerical financial or operational metrics such as revenue, net income, gross margin, operating profit, cash flow figures, or segment-specific data.

Perrigo | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 1.11 B